# **Review** Article

# Clinical Efficacy and Safety of Eight Traditional Chinese Medicine Combined with Entecavir in the Treatment of Chronic Hepatitis B Liver Fibrosis in Adults: A Network Meta-Analysis

Tao Wang,<sup>1,2</sup> Wei Jin,<sup>3</sup> Qianqian Huang,<sup>1</sup> Haotian Li,<sup>2</sup> Yun Zhu,<sup>4</sup> Honghong Liu,<sup>4</sup> Huadan Cai,<sup>2</sup> Jiabo Wang,<sup>5</sup> Ruilin Wang,<sup>4</sup> Xiaohe Xiao,<sup>5</sup> Yanling Zhao,<sup>2</sup> and Wenjun Zou,<sup>1</sup>

<sup>1</sup>College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China <sup>2</sup>Department of Pharmacy, 302 Military Hospital of China, Beijing 100039, China <sup>3</sup>Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China

<sup>4</sup>Integrative Medical Center, 302 Military Hospital of China, Beijing 100039, China

<sup>5</sup>China Military Institute of Chinese Medicine, 302 Military Hospital of China, Beijing 100039, China

Correspondence should be addressed to Yanling Zhao; 2964842070@qq.com and Wenjun Zou; zouwenjun@163.com

Received 10 June 2020; Accepted 5 August 2020; Published 30 September 2020

Guest Editor: Hongwei Zhang

Copyright © 2020 Tao Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Background*. Traditional Chinese medicine (TCM) is used as an adjuvant drug for the treatment of chronic hepatitis B liver fibrosis and is used frequently. We still do not know which TCM has the best curative effect as an adjuvant drug. Therefore, we decided to use network meta-analysis to solve this problem. *Methods*. We used the RevMan software (5.3) and Stata software (13.0) to achieve this network meta-analysis (NMA). The primary outcomes of this study were HA, LN, PCIII, and IV-C; the secondary outcomes of this study were AST, ALT, and HBV-DNA negative conversion rate, and the Cochrane risk-of-bias tool was used to assess the quality of the included studies. For all outcomes, the scissors funnel plot, Egger test, and Begg test were used to detect publication bias, and sensitivity analysis was used to investigate the stability of the results. And the meta-regression was used to explore the source of heterogeneity. *Results*. A total of 34 articles were included in this study. The study involved a total of 3199 patients, of which 1578 were assigned to the control group and 1621 patients were assigned to the experimental group. The number of men and women is roughly equal, and the average age is about 43 years old. In addition, nine treatment strategies were involved in this study. The combination of TCM and entecavir can significantly improve the patients' HA, LN, PCIII, IV-C, AST, ALT, and HBV-DNA negative conversion rates. The comprehensive evaluation results showed that FHC combined with entecavir has more advantages than other treatment strategies. *Conclusion*. For improving the HBV-DNA negative conversion rates, adding TCM to the therapeutic strategies does not seem to show absolute superiority. Finally, FHC combined with entecavir is the best therapeutic strategy.

# 1. Introduction

Chronic hepatitis B (CHB) is one of the most serious infectious diseases in the world today. It has extremely high morbidity and mortality, and it is a serious threat to human health [1, 2]. Every year, more than 600,000 people die from hepatitis B virus (HBV)-related diseases in the world [3]. Liver fibrosis, which as a process of hepatic repair and healing, can eventually develop into cirrhosis or even liver cancer if the liver damage factors cannot be removed over a long period of time. In addition, hepatitis B virus is one of the most common causes of liver cirrhosis in China. Statistical studies have shown that 3% of patients with chronic hepatitis B (CHB) have decompensated liver cirrhosis every year, 2% to 8% of patients have primary liver cancer, and once they progress to decompensation liver cirrhosis, its 5year cumulative survival rate was only 14% to 35% [4]. Therefore, for liver fibrosis, which as the starting point for serious liver disease, if this process can be well inhibited, it will be able to prevent liver disease from worsening in time.

At present, nucleoside (acid) analogues are mainly used clinically to treat hepatitis B liver fibrosis, such as adefovir dipivoxil, entecavir, and tenofovir disoproxil, which mainly through the continuous suppression of HBV-DNA replication to alleviate B hepatitis liver fibrosis. In particular, entecavir has become one of the main first-line drugs for the treatment of liver fibrosis in chronic hepatitis B in China. However, the use of Western medicine (such as entecavir) for the treatment of chronic hepatitis B liver fibrosis has a long cycle of treatment and even requires the patient to take medicine for life, causing a certain burden on the patient's family and greatly affecting the patient's own quality of life. And entecavir is a kind of guanine nuclear analog, although it has good safety, but there are still some studies reported that it caused lactic acidosis [5]. However, the cost of TCM treatment is relatively low, and TCM can act on multiple targets in the body at the same time. Many studies have shown that the use of Chinese and Western medicine in the treatment of chronic hepatitis B liver fibrosis can achieve better effect [6].

In China, there are many types of TCM used by clinicians in the treatment of chronic hepatitis B liver fibrosis. Among them, there are 8 kinds of TCM used as first-line drugs and included in the Chinese Pharmacopoeia: Anluo Huaxian Pill (AHP), Dahuang Zhechong Capsule (DZC), and Tanshinone Capsule (TSC), Danshen Injection (DI), Fuzheng Huayu Capsule (FHC), Biejia Ruangan Tablet (BRT), Danshendi Tablet (DDT), and Liuwei Wuling Tablet (LWT). The efficacy of these commonly used TCM is definite, and combined with the current first-line drug entecavir can significantly improve the clinical efficacy. This conclusion is not only due to long-term clinical experience. In recent years, many scholars have used meta-analysis and systematic review of evidence-based medical research methods to analyze the efficacy of the joint use of Chinese and Western medicine. Wang et al. showed that FHC combined with entecavir can significantly improve liver function and liver fibrosis in chronic hepatitis B patients [7]. Duan et al. also reached a similar conclusion when studying the effect of BRT combined with entecavir on the improvement of chronic hepatitis B cirrhosis [8]. In addition, LWT and AHP are also good auxiliary drugs [9, 10]. Although some researchers use meta-analysis methods to compare different treatment strategies, each comparison can only solve the problem of which of the two treatment strategies is better. When doctors choose treatment strategies, there are many kinds of TCM that can be selected, and which kind of TCM can achieve the best effect when used as an auxiliary medicine. This is still a problem that cannot be ignored. Therefore, we use the NMA to compare and rank the safety and effectiveness of the 8 TCMs which often used for adjuvant treatment of chronic hepatitis B liver fibrosis.

## 2. Materials and Methods

2.1. Search Strategy and Selection Criteria. We searched China National Knowledge Infrastructure, Wanfang Database, VIP medicine information system, PubMed, Embase, and Cochrane Library. The search time ranges from database establishment to May 2018. The initial search items were used as follows: "Fuzheng Huayu capsule," "Biejia Ruangan Tablets," "Liuwei Wuling Tablets," "Anluo Huaxian Pills," "Dahuang Zhechong Pills," "Tanshinone capsules," "Danshen Injection," "Entecavir," and "Chinese Medicine" [Title/Abstract] AND "Chronic hepatitis B liver fibrosis" [Title/Abstract] OR "Chronic hepatitis B" [Title/Abstract] OR "Liver Fibrosis" [Title/Abstract] OR "Hepatitis B" [Title/ Abstract]. And the full text of the search results is downloaded. The inclusion criteria were as follows: (1) all randomized controlled trials (RCTs) and semirandomized controlled trials of Chinese Medicine combine with entecavir were included. (2) Chronic hepatitis B liver fibrosis was diagnosed according to definite diagnostic criteria. (3) The studies with an experimental group using entecavir combined with Chinese medicine and the control using entecavir were included. (4) The gender and age of patients were not limited. (5) The language of the literature is not limited. The exclusion criteria were as follows: (1) the repeated published literature, (2) studies with incomplete or incorrect data, (3) control group combined with other medicine during treatment, and (4) animal experiments and the review literature. And all patients were not treated with drugs such as interferon or nucleoside (acid) for six months before treatment.

2.2. Data Extraction and Quality Assessment. Three researchers (Tao Wang, Yanling Zhao, and Haotian Li) independently performed data extraction and quality assessment. Two researchers (Qianqian Huang and Huadan Cai) formed a review team to independently verify the accuracy of data extraction, quality assessment, and all materials for this study. Basic information was extracted from the included studies (name of the study included, average age of patients, number of patients, therapeutic strategies, mode of administration, dose administered, course of treatment, outcome, etc.) (Supplementary Table 1). The primary outcomes of this study were HA, LN, PCIII, and IV-C; the secondary outcomes of this study were AST, ALT, and HBV-DNA negative conversion rate, and the Cochrane Risk of Bias tool was used to assess the quality of the included studies. All the differences that occurred in the study were discussed by three researchers, and they were then agreed by the review team.

2.3. Statistical Analysis. We performed this study using RevMan software (5.3) and Stata software (13.0) and constructed a treatment strategy network. For the continuous variables, we calculated the normalized mean difference (MD), and for the dichotomous variable, we calculated the odds ratios (ORs). All of them were expressed with 95% CI. We compared each therapeutic strategy in pairs.

Subsequently,  $I^2$  and chi-square tests were used to assess the heterogeneity between therapeutic strategies, and we use meta-regression to explore the source of heterogeneity. For all outcomes, the shear funnel plot, Egger test, and Begg test were used to detect publication bias, and sensitivity analysis was used to investigate the stability of the results. For all outcomes, the scissors funnel plot, Egger test, and Begg test were used to detect publication bias, and sensitivity analysis was used to investigate the stability of the results. For all outcomes, the scissors funnel plot, Egger test, and Begg test were used to detect publication bias, and sensitivity analysis was used to investigate the stability of the results. Finally, we used the surface under the cumulative ranking curve (SUCRA) to rank the efficacy of the therapeutic strategy in each outcome. In addition, we did this NMA within a frequentist framework.

2.4. Statement. This study is registered with PROSPERO, number CRD42018095445. Finally, we need to state that the research funders did not interfere with any aspect of research design, data collection, data analysis, data interpretation, and article writing.

#### 3. Results and Discussion

#### 3.1. Results

3.1.1. Quality and Characteristics of the Included Studies. Through the key words in the search strategy, a total of 4969 articles were obtained, of which 3455 were excluded from repetitive reports, 68 articles were excluded from the review, and 1288 articles that did not use TCM+entecavir as a treatment strategy were excluded. In addition, we also excluded 124 articles which the control group did not use entecavir alone or experiment group combination with a variety of TCM, and eventually included 34 articles [11-44] (Figure 1(a)). In the literature included in this study, a total of 7 studies reported the randomization method, 7 studies did not adopt a completely random grouping method, and the rest of the studies only mentioned randomized grouping but did not explicitly report the randomization method. In terms of data integrity, 28 studies have good data integrity, 5 studies cannot clearly determine whether the data are complete, and 1 study has missing data. In addition, unfortunately, all the included studies did not explicitly mention the blinding method, so they could not judge whether they had adopted the blinding method in the trial. However, there are no selective reports in all the included studies. We assessed the quality of included studies in accordance with the Cochrane risk-of-bias tool. Each evaluation principle was divided into "high risk," "low risk," and "unclear" (Figure 1(b)). All the studies included in this study were designed in parallel, and the test sites were all in China. All patients were diagnosed with chronic hepatitis B liver fibrosis according to definite diagnostic criteria and confirmed in regular hospitals. The control group was given entecavir, and the experimental group was combined with a traditional Chinese medicine based on the treatment strategy of the control group. The study involved a total of 3199 patients, of which 1578 were assigned to the control group and 1621 patients were assigned to the experimental group. The number of men and women is roughly equal, and

the average age is about 43 years old. In addition, nine treatment strategies were involved in this study (Figure 1(c)).

3.1.2. Primary Outcomes. The primary outcomes of our study were liver fibrosis (HA, LN, PCIII, and IV-C). All the included studies have reported on these four indicators. Compared with entecavir alone, we found that TCM combined with entecavir can significantly improve liver fibrosis in patients (HA: MD = -57.15, 95% CI: -69.06-45.25, *P* < 0.00001; LN: MD = -35.04, 95% CI: -43.32-26.76, P < 0.00001; PCIII: MD = -29.32, 95% CI: -31.68-26.96, *P* < 0.00001; IV-C: MD = -38.98, 95% CI: -48.32-29.64, P < 0.00001) (Figure 2). We considered the internal heterogeneity of the studies, so we decided to use the random-effects model for data analysis. Moreover, in order to further verify the reliability of the results of this study, we use sensitivity analysis (Table 1) to explore the stability of the results and use funnel charts and statistical tests (Egger test and Begg test) to explore whether there is publication bias (Table 1 and Supplementary Figures 1-4). As a result, it was found that some of the results of this study were unstable, but most of the studies were stable and there was no significant publication bias. In addition, our meta-regression showed that the difference in sample size between the studies did not cause significant heterogeneity. The difference in therapeutic strategies is the main source of heterogeneity in this study (Table 1).

Based on the above results, we use Stata software to make a mixed comparison of all therapeutic strategies and calculate the OR value (Supplementary Tables 2-5), which also helps to eliminate the heterogeneity caused by the variety of therapeutic strategies between studies. Subsequently, based on the effect of various therapeutic strategies on liver fibrosis improvement, we use SUCAR charts to rank treatment decisions and calculate the average ranking of each therapeutic strategies to further explore which TCM as an adjuvant drug is the best therapeutic strategies (Figure 3). The results showed that FHC (2.25), TSC (3.25), and LWT (3.75) were the top three, followed by BRT (4.00), DI (4.50), DDT (4.75), DZC (6.00), and entecavir (7.50). The combination of AHP (9) and entecavir was the most unfavorable treatment strategy. Since direct and indirect comparisons between treatment strategies all contribute to the final results, we finally calculated the contribution of the direct and indirect comparisons to the final results in order to make the results of this study clearer, and the detailed results of this section are listed in the annex (Supplementary Figure 5).

3.1.3. Secondary Outcomes. There are 3 secondary outcomes in our study: liver function index (AST and ALT) and HBV-DNA negative conversion rate. A total of 13 studies reported the improvement of HBV-DNA negative conversion rate by TCM; 21 studies reported the improvement of ALT and AST by TCM. Our research found that (Figure 4) entecavir combined with TCM compared to entecavir alone and HBV-DNA negative conversion rate did not show a significant difference (OR = 1.27, 95% CI: 0.92–1.76, P = 0.14) but significantly improved ALT and AST (MD = -13.33, 95% CI:




FIGURE 1: (a) Flowchart of study selection; (b) methodological quality assessment of the risk of bias for each included study; (c) network of eligible comparisons of efficacy of treatment.

-16.99-9.68, P < 0.00001; MD = -9.92, 95% CI: -13.40-6.44, P < 0.00001). In order to further explore the stability of the results and whether the results were affected by potential biases, we performed sensitivity analyses (Table 1), scissors

funnel plot (Supplementary Figures 6–8), Egger test, and Begg test (Table 1). We found that the results of this study were stable, there was a slight publication bias in HBV-DNA negative conversion rate, and there was no significant

Study or subgroup	Experimental				Control V		Weight		Mean difference
study of subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% CI	IV, random, 95% CI
C Xie 2016	88	24	50	100.42	34.52	50	3.1	-12.42 [-24.07, -0.77]	
CR Shen 2010	98.64	30.78	46	151.05	43.12	50	3.1	-52.41 [-67.31, -37.51]	
DJ Chen 2017	110.5	33.4	36	153.4	44.6	36	3.0	-42.90 [-61.10, -24.70]	
F Zhang 2017	121	28.3	35	170.8	36.8	35	3.1	-49.80 [-65.18, -34.42]	
FL Long 2011	82.4	32.2	57	189.6	24.1	59	3.2	-107.20 [-117.58, -96.82]	
GQ Chen 2016	66.27	19.18	45	103.3	37.21	45	3.1	-37.03 [-49.26, -24.80]	
HD Qi 2008	110.7	84.5	30	194.7	95.3	28	2.2	-84.00 [-130.48, -37.52]	
HS Xie 2016	124.7	65.8	65	156.3	82.7	63	2.8	-31.60 [-57.54, -5.66]	
HT Zhang 2015	106.8	81.8	100	142.5	91.2	100	2.9	-35.70 [-59.71, -11.69]	
J Shi 2013	149.3	92.5	20	204.5	69.8	20	2.0	-55.20 [-105.99, -4.41]	
JH Zhang 2014	105.4	23.5	23	136.2	26.3	23	3.1	-30.80 [-45.21, -16.39]	
L Xiao 2013	110.4	33.5	54	153.3	44.7	54	3.1	-42.90 [-57.80, -28.00]	
LL Wu 2013	86.2	23.3	55	141.6	23.8	55	3.2	-55.40 [-64.20, -46.60]	-
Q Yang 2015	85.3	20.1	50	100.3	52.4	50	3.1	-15.00 [-30.56, 0.56]	
RF Zhang 2014	98.97	50.42	57	130.12	49.89	55	3.0	-31.15 [-49.73, -12.57]	
RQ Fan 2013	95.6	47.6	38	203.7	73.4	35	2.7	-108.10 [-136.74, -79.46]	
SQ Pang 2013	88.5	28.7	50	128	22.9	50	3.2	-39.50 [-49.68, -29.32]	
W Guo 2010	137.4	68.4	43	174.8	72.6	42	2.7	-37.40 [-67.40, -7.40]	
XL Zhang 2016	101.7	30.1	63	182.2	87.7	71	2.9	-80.50 [-102.21, -58.79]	
XP Pan 2016	95.6	28.5	50	187.5	37	50	3.1	-91.90 [-104.85, -78.95]	
XQ Chen 2016	116.54	36.77	68	133.57	26.6	68	3.2	-17.03 [-27.82, -6.24]	
Y Zuo 2015	181.4	51.8	43	285	17.6	43	3.1	-103.60 [-119.95, -87.25]	_ <b>_</b>
YH Gong 2010	106	30.2	28	196.6	38.2	24	3.0	-90.60 [-109.54, -71.66]	
YH Zeng 2013	145.4	86.5	30	249.3	116.5	30	2.0	-103.90 [-155.82, -51.98]	
YJ Qiu 2017	77.5	52.1	64	221.9	50.15	64	3.0	-144.40 [-162.12, -126.68]	
YL Fan 2009	107.4	39.79	28	133	46.4	26	2.9	-25.60 [-48.74, -2.46]	
YQ Zhao 2015	95.3	25.1	57	133.5	30.3	55	3.2	-38.20 [-48.52, -27.88]	
YY Sun 2017	190.25	13.12	38	198.13	14.15	38	3.2	-7.88 [-14.02, -1.74]	-
YZ Song 2012	126.2	47.7	36	172.7	65.4	32	2.8	-46.50 [-74.00, -19.00]	
ZF Shangguan 2013	98.7	28.8	41	160.9	60.8	40	2.9	-62.20 [-83.00, -41.40]	
ZG Wu 2017	67.8	42.7	45	99.4	46.7	47	3.0	-31.60 [-49.87, -13.33]	
ZG Zhang 2012	91.3	43.5	43	187.5	56.3	43	2.9	-96.20 [-117.47, -74.93]	
ZH Hu 2016	94.2	30.28	43	185.38	40.05	43	3.1	-91.18 [-106.19, -76.17]	<u> </u>
ZJ Huang 2016	75.3	9.1	68	146.5	34.3	66	3.2	-71.20 [-79.75, -62.65]	
Total (95% CI)			1599			1590	100.0	-57.15 [-69.06, -45.25]	◆
Heterogeneity: tau <sup>2</sup> =				= 33 (P <	0.00001	); $I^2 = 96$	5%		-100 -50 0 50 100
Test for overall effect: $Z = 9.41$ ( $P < 0.00001$ )								55 5 55 100	

(a)

C	Ex	operimen	tal		Control		Weight	Mean difference	Mean difference
Study or subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% CI	IV, random, 95% CI
C Xie 2016	27.86	10	43	32.58	4.88	43	3.4	-4.72 [-8.05, -1.39]	-
CR Shen 2010	68.35	18.32	46	114.16	40.18	50	3.2	-45.81 [-58.14, -33.48]	- <del>-</del> -
DJ Chen 2017	165.8	58.7	36	113.6	30.1	36	2.8	52.20 [30.65, 73.75]	
F Zhang 2017	130.7	36.4	35	160.3	41.3	35	2.9	-29.60 [-47.84, -11.36]	
FL Long 2011	102.5	26.6	57	122.9	23.6	59	3.3	-20.40 [-29.56, -11.24]	-
GQ Chen 2016	95.53	27.65	45	149.17	39.23	45	3.1	-53.64 [-67.66, -39.62]	
HD Qi 2008	107.1	21.7	30	126.8	24.8	28	3.2	-19.70 [-31.73, -7.67]	
HS Xie 2016	79.8	62.5	65	95.3	78.4	63	2.6	-15.50 [-40.11, 9.11]	
HT Zhang 2015	125.4	72.2	100	155.2	77.6	100	2.8	-29.80 [-50.57, -9.03]	
J Shi 2013	131.8	64.37	20	119.21	55.62	20	2.0	12.59 [-24.69, 49.87]	
JH Zhang 2014	126.3	24.8	23	167.3	27.3	23	3.1	-41.00 [-56.07, -25.93]	
L Xiao 2013	90.7	28.3	54	113.5	30.2	54	3.2	-22.80 [-33.84, -11.76]	
LL Wu 2013	76.5	18.4	55	127.2	36.4	55	3.2	-50.70 [-61.48, -39.92]	-
Q Yang 2015	100.5	25	50	256.3	55.6	50	3.0	-155.80 [-172.70, -138.90]	
RF Zhang 2014	132.48	101.83	57	178.8	99.5	55	2.0	-46.32 [-83.61, -9.03]	
RQ Fan 2013	87.5	33.2	38	151.4	68.3	35	2.6	-63.90 [-88.87, -38.93]	
SQ Pang 2013	92.1	35.3	50	100.2	25.1	50	3.2	-8.10 [-20.11, 3.91]	
W Guo 2010	139.1	85.4	43	164.3	93.8	42	2.0	-25.20 [-63.36, 12.96]	
XL Zhang 2016	147.4	41.1	63	183.5	56.4	71	3.0	-36.10 [-52.69, -19.51]	
XP Pan 2016	85.3	21.5	50	135.6	29.6	50	3.2	-50.30 [-60.44, -40.16]	-
XQ Chen 2016	64.23	11.63	68	82.61	14.37	68	3.4	-18.38 [-22.77, -13.99]	-
Y Zuo 2015	125	34.9	43	185	45.2	43	3.0	-60.00 [-77.07, -42.93]	
YH Gong 2010	123.3	61.5	28	228.3	51.3	24	2.3	-105.00 [-135.66, -74.34]	(
YH Zeng 2013	135.6	78.6	30	182.3	72.5	30	2.0	-46.70 [-84.96, -8.44]	
YJ Qiu 2017	66.2	18.5	64	109.9	23.4	64	3.3	-43.70 [-51.01, -36.39]	-
YL Fan 2009	130.93	51.08	28	169.03	58.72	26	2.4	-38.10 [-67.55, -8.65]	
YQ Zhao 2015	56.4	9.5	57	82.6	15.6	55	3.4	-26.20 [-31.00, -21.40]	-
YY Sun 2017	73.34	5.67	38	70.15	5.12	38	3.4	3.19 [0.76, 5.62]	-
YZ Song 2012	96.4	33.1	36	122.5	35.2	32	3.0	-26.10 [-42.40, -9.80]	
ZF Shangguan 2013	78.4	26.3	41	126.6	46.3	40	3.0	-48.20 [-64.65, -31.75]	
ZG Wu 2017	103.1	20.2	45	132.7	23.8	47	3.3	-29.60 [-38.61, -20.59]	-
ZG Zhang 2012	102.3	30.9	43	142.8	41.6	43	3.1	-40.50 [-55.99, -25.01]	
ZH Hu 2016	84.79	20.82	43	132.47	28.26	43	3.2	-47.68 [-58.17, -37.19]	-
ZJ Huang 2016	80.4	9.5	68	103.6	15.6	66	3.4	-23.20 [-27.59, -18.81]	-
Total (95% CI)			1592			1583	100.0	-35.04 [-43.32, -26.76]	•
Heterogeneity: tau <sup>2</sup> =				33 ( <i>P</i> < 0	.00001);	$I^2 = 979$	6	_	-100 -50 0 50 100
Test for overall effect	7 - 9 20	(D < 0.00)	001)						

	Ex	perimen	ital		Control		Weight	Mean difference	Mean difference
Study or subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% CI	IV, random, 95% CI
C Xie 2016	20.76	7	50	28.69	5.7	50	8.8	-7.93 [-10.43, -5.43]	-
CR Shen 2010	188.08	58.55	46	250.12	55.23	50	1.0	-62.04 [-84.86, -39.22]	
DJ Chen 2017	122.8	31.3	36	145.7	33.8	36	2.0	-22.90 [-37.95, -7.85]	
F Zhang 2017	96.8	27.8	35	160.1	39.7	35	1.8	-63.30 [-79.36, -47.24]	
FL Long 2011	92.8	10	57	126.5	53.3	59	2.2	-33.70 [-47.55, -19.85]	
GQ Chen 2016	186.1	47.53	45	159.12	49.14	45	1.2	26.98 [7.01, 46.95]	
HD Qi 2008	111.2	33.3	30	149.5	50.1	28	1.0	-38.30 [-60.35, -16.25]	
HS Xie 2016	86.4	78.7	65	115.3	90.6	63	0.6	-28.90 [-58.34, 0.54]	
HT Zhang 2015	0.6	0.3	100	1	0.6	100	9.8	-0.40 [-0.53, -0.27]	+
J Shi 2013	44.41	11.56	20	58.7	15.36	20	4.4	-14.29 [-22.72, -5.86]	-
JH Zhang 2014	102.1	24.2	23	139.1	28.3	23	1.9	-37.00 [-52.22, -21.78]	
L Xiao 2013	122.7	31.4	54	145.6	33.9	54	2.7	-22.90 [-35.22, -10.58]	
LL Wu 2013	72.3	41.2	55	241.2	69.2	55	1.1	-168.90 [-190.18, -147.62]	
Q Yang 2015	103.4	20.1	50	200.8	35.6	50	3.0	-97.40 [-108.73, -86.07]	
RF Zhang 2014	117.96	26.02	57	131.98	28.03	55	3.5	-13.97 [-24.00, -3.94]	-
RQ Fan 2013	83.2	41.8	38	167.6	81.4	35	0.6	-84.40 [-114.46, -54.34]	
SQ Pang 2013	88.7	26.9	50	108.3	22.9	50	3.7	-19.60 [-29.39, -9.81]	-
W Guo 2010	78.3	56.8	43	92.4	52.96	42	0.9	-14.10 [-37.44, 9.24]	
XL Zhang 2016	32.3	12.7	63	89.1	19.2	71	6.4	-56.80 [-62.26, -51.34]	÷
XP Pan 2016	80.5	18.7	50	130.5	35.3	50	3.1	-50.00 [-61.07, -38.93]	
XQ Chen 2016	101.45	18.66	68	122.57	26.39	68	4.8	-21.12 [-28.80, -13.44]	-
Y Zuo 2015	94.3	42	43	178	51.8	43	1.2	-83.70 [-103.63, -63.77]	
YH Gong 2010	103.2	40.5	28	151.8	52.6	24	0.8	-48.60 [-74.44, -22.76]	
YH Zeng 2013	91.6	50.1	30	156.7	52.8	30	0.8	-65.10 [-91.15, -39.05]	
YJ Qiu 2017	99.8	31.9	64	158.9	50.1	64	2.1	-59.10 [-73.65, -44.55]	
YL Fan 2009	104.37	22.17	28	140.17	23.21	26	2.7	-35.80 [-47.93, -23.67]	
YQ Zhao 2015	99.5	17.4	57	117.2	3.1	55	7.2	-17.70 [-22.29, -13.11]	+
YY Sun 2017	8.2	0.61	38	8.9	0.27	38	9.8	-0.70 [-0.91, -0.49]	+
YZ Song 2012	99.5	28.8	36	115.7	30.8	32	2.2	-16.20 [-30.43, -1.97]	
ZF Shangguan 2013	70.3	50.8	41	240.6	77.6	40	0.6	-170.30 [-198.94, -141.66]	
ZG Wu 2017	73.6	62.3	45	102.5	65.9	47	0.8	-28.90 [-55.10, -2.70]	
ZG Zhang 2012	122.4	61.3	43	242.5	70.8	43	0.7	-120.10 [-148.09, -92.11]	
ZH Hu 2016	79.15	19.35	43	125.4	38.14	43	2.5	-46.25 [-59.03, -33.47]	
ZJ Huang 2016	89.5	18.4	68	127.2	31.4	66	4.2	-37.70 [-46.45, -28.95]	-
Total (95% CI)			1599			1590	100.0	-29.32 [-31.68, -26.96]	•
Heterogeneity: tau <sup>2</sup> =	14.80; ch	i <sup>2</sup> = 189	4.00, df =	= 33 ( <i>P</i> <	0.00001)	$I^2 = 989$	%		-100 -50 0 50 100
Test for overall effect: $Z = 24.34$ ( $P < 0.00001$ )								Favours (control) Favours (experiment	

(c)

Study or subgroup	Ex	perimen	ital		Control		Weight	Mean difference	Mean difference		
study of subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% CI	IV, random, 95% CI		
C Xie 2016	21.33	7	50	24.96	8.76	50	3.1	-3.63 [-6.74, -0.52]	-		
CR Shen 2010	94.55	21.25	46	155.45	40.18	50	3.0	-60.90 [-73.62, -48.18]			
DJ Chen 2017	97.3	35.7	36	123.7	40.5	36	2.8	-26.40 [-44.04, -8.76]			
F Zhang 2017	72.6	20.6	35	98.8	25.7	35	3.0	-26.20 [-37.11, -15.29]	-		
FL Long 2011	72.5	10.7	57	80.2	11.3	59	3.1	-7.70 [-11.70, -3.70]	-		
GQ Chen 2016	95.43	23.32	45	160.5	38.22	45	3.0	-65.07 [-78.15, -51.99]			
HD Qi 2008	78.1	17.2	30	89.3	16.9	28	3.1	-11.20 [-19.98, -2.42]			
HS Xie 2016	85.4	40.7	65	103.4	52.7	63	2.9	-18.00 [-34.35, -1.65]			
HT Zhang 2015	90.6	79.1	100	134.2	67.7	100	2.7	-43.60 [-64.01, -23.19]			
J Shi 2013	74.28	21.69	20	86.54	19.58	20	3.0	-12.26 [-25.07, 0.55]			
JH Zhang 2014	46.9	12.9	23	78.8	18.3	23	3.0	-31.90 [-41.05, -22.75]	-		
L Xiao 2013	97.2	35.8	54	123.6	40.6	54	2.9	-26.40 [-40.84, -11.96]			
LL Wu 2013	62.3	15.6	55	140.5	46.8	55	3.0	-78.20 [-91.24, -65.16]			
Q Yang 2015	85.6	36.4	50	258.7	22.6	50	3.0	-173.10 [-184.98, -161.22]	-		
RF Zhang 2014	172.4	58.16	57	218.13	75.32	55	2.6	-45.73 [-70.71, -20.75]			
RQ Fan 2013	76.5	21.4	38	104.6	37.8	35	2.9	-28.10 [-42.35, -13.85]			
SQ Pang 2013	66.3	21.2	50	116.8	34.49	50	3.0	-50.50 [-61.72, -39.28]	-		
W Guo 2010	72.8	33.2	43	91.7	38.7	42	2.9	-18.90 [-34.24, -3.56]			
XL Zhang 2016	38.9	9.4	63	74.9	31.3	71	3.1	-36.00 [-43.64, -28.36]	-		
XP Pan 2016	72.7	22.6	50	88.5	20.4	50	3.1	-15.80 [-24.24, -7.36]	-		
XQ Chen 2016	73.65	10.02	68	106.22	17.39	68	3.1	-32.57 [-37.34, -27.80]	-		
Y Zuo 2015	89	31.2	43	156	44.9	43	2.9	-67.00 [-83.34, -50.66]			
YH Gong 2010	86.1	23.2	28	145.5	26.3	24	2.9	-59.40 [-72.99, -45.81]			
YH Zeng 2013	69.4	12.5	30	105.2	81.2	30	2.4	-35.80 [-65.20, -6.40]			
YJ Qiu 2017	70.1	22.1	64	89.9	23.1	64	3.1	-19.80 [-27.63, -11.97]			
YL Fan 2009	47.97	33.3	28	73.53	32.03	26	2.8	-25.56 [-42.99, -8.13]			
YQ Zhao 2015	90.1	16.5	57	132.6	25.7	55	3.1	-42.50 [-50.53, -34.47]			
YY Sun 2017	115.32	10.11	38	122.15	11.56	38	3.1	-6.83 [-11.71, -1.95]	-		
YZ Song 2012	92.3	30.9	36	128.1	39.7	32	2.8	-35.80 [-52.86, -18.74]			
ZF Shangguan 2013	60.8	30.6	41	140.2	50.3	40	2.8	-79.40 [-97.59, -61.21]			
ZG Wu 2017	78.2	26.2	45	108.7	35.9	47	3.0	-30.50 [-43.30, -17.70]			
ZG Zhang 2012	104.9	31.9	43	170.4	51.7	43	2.8	-65.50 [-83.66, -47.34]			
ZH Hu 2016	74.1	20.28	43	97.39	22.46	43	3.0	-23.29 [-32.33, -14.25]	-		
ZJ Huang 2016	90.4	23.5	68	122.6	18.7	66	3.1	-32.20 [-39.38, -25.02]	-		
Total (95% CI)			1599			1590	100.0	-38.98 [-48.32, -29.64]	◆		
Heterogeneity: tau <sup>2</sup> =	= 723.28; c	:hi <sup>2</sup> = 12	25.36, df	= 33 (P <	0.00001	); $I^2 = 97$	7%		-100 -50 0 50 100		
Test for overall effect	: Z = 8.18	( <i>P</i> < 0.0	0001)								
			,						Favours (control) Favours (experimental)		

FIGURE 2: (a) The HA of TCM plus entecavir versus entecavir. (b) The LN of TCM plus entecavir versus entecavir. (c) The PCIII of TCM plus entecavir versus entecavir. (d) The IV-C of TCM plus entecavir versus entecavir.  $l^2$  and P are the criterion for the heterogeneity test,  $\blacklozenge$  pooled odds ratio,  $-\blacksquare$  odds ratio, and 95% CI.

(d)

TABLE 1: The table of sensitivity analysis, bias test, and meta-regression.

Outcome	Fixed model	Random model	Begg test (P)	Egger test (P)	Meta-regression (P)
НА	MD = -48.59, 95%	MD = 57.15, 95%	0.882	0.878	0.610; 0.007
ПА	CI: -51.00-46.18	CI: -69.06-45.25	0.002	0.878	0.010; 0.007
LN	MD = -18.37, 95%	MD = -35.04, 95%	0.534	0.565	0.341; 0.033
LIN	CI: -19.69-17.00	CI: -43.32-26.78	0.334	0.303	0.341, 0.033
PCIII	MD = -31.17, 95%	MD = -29.32, 95%	0.767	0.902	0.902; 0.071
rum	CI: -33.68-28.68	CI: -31.68-26.96	0.707	0.902	0.902, 0.071
IV-C	MD = -23.46, 95%	MD = -38.98, 95%	0.813	0.665	0.627; 0.303
10-0	CI: -24.91-22.00	CI: -48.32-29.64	0.015	0.005	0.027, 0.303
AST	MD = -10.82, 95%	MD = -9.92, 95%	0.415	0.877	0.987; 0.866
A31	CI: -12.10-9.55	CI: -13.40-6.44	0.415	0.877	0.987, 0.800
ALT	MD = -15.69, 95%	MD = -13.33, 95%	0.608	0.153	0.496; 0.570
ALI	CI: -16.94-14.45	CI: -16.99-9.68	0.008	0.155	0.490, 0.370
HBV-DNA	OR = 1.27, 95%	OR = 1.33, 95%	0.012	0.017	0.010; 0.722
IID V-DINA	CI: 0.92-1.76	CI: 0.86-2.07	0.012	0.017	0.010; 0.722





FIGURE 3: Continued.



(c) FIGURE 3: Continued.




FIGURE 3: (a) Ranking for efficacy of HA; (b) ranking for efficacy of LN; (c) ranking for efficacy of PCIII; (d) ranking for efficacy of IV-C.

Ct. 1	Experi	mental	Cor	itrol	Weight	Odds ratio		Odd	s ratio	
Study or subgroup	Events	Total	Events	Total	(%)	M-H, fixed, 95% CI		M-H, fix	ed, 95% CI	
F Zhang 2017	33	35	31	35	2.7	2.13 [0.36, 12.46]				
GQ Chen 2016	29	45	26	45	14.1	1.32 [0.57, 3.10]				
HD Qi 2008	28	30	25	28	2.6	1.68 [0.26, 10.89]			· · · · · · · · · · · · · · · · · · ·	
JH Zhang 2014	22	23	15	23	1.0	11.73 [1.33, 103.80]			· · · · ·	
RF Zhang 2014	50	57	47	55	9.0	1.22 [0.41, 3.62]				
RQ Fan 2013	35	38	32	35	4.0	1.09 [0.21, 5.81]				
XP Pan 2016	45	50	44	50	6.7	1.23 [0.35, 4.32]			+•	
YC Xie 2016	37	50	34	50	13.5	1.34 [0.56, 3.19]			-	
YL Fan 2009	28	30	26	30	2.6	2.15 [0.36, 12.76]				
YY Sun 2017	8	38	1	38	1.2	9.87 [1.17, 83.35]			·	
ZG Wu 2017	37	45	38	47	10.1	1.10 [0.38, 3.14]				
ZH Hu 2016	40	43	38	43	4.1	1.75 [0.39, 7.85]				
ZJ Huang 2016	45	66	59	68	28.3	0.33 [0.14, 0.78]				
Total (95% CI)		550		547	100.0	1.27 [0.92, 1.76]			•	
Total events	437		416							
Heterogeneity: chi <sup>2</sup> =	17.93, df =	12 (P = 0.12)	2); $I^2 = 33\%$				0.01	0.1	1 10	10
Test for overall effect	: Z = 1.46 (P	= 0.14)					0.01	Favours (control)	Favours (experimental	

(a) FIGURE 4: Continued.

0.1.1	Ex	perimen	ital		Control		Weight	Mean difference	Mean	difference
Study or subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% CI	IV, rand	dom, 95% CI
C Xie 2016	28.7	14	50	34.98	25.26	50	4.7	-6.28 [-14.29, 1.73]		+
CR Shen 2010	51.2	20.1	46	57.5	38.6	50	3.6	-6.30 [-18.47, 5.87]		
F Zhang 2017	28.4	7.7	35	43.8	8.3	35	5.7	-15.40 [-19.15, -11.65]		
FL Long 2011	36.8	8.5	57	61.6	5.81	59	5.9	-24.80 [-27.46, -22.14]	-	
GQ Chen 2016	24.3	15.8	45	43.6	18.9	45	4.9	-19.30 [-26.50, -12.10]		
HS Xie 2016	25.3	22.6	65	36.6	24.9	63	4.7	-11.30 [-19.55, -3.05]		-
HT Zhang 2015	54.2	22.5	100	65.2	26.7	100	5.0	-11.00 [-17.84, -4.16]		
L Xiao 2010	49.8	17.6	54	58.4	22.7	54	4.8	-8.60 [-16.26, -0.94]		-
LL Wu 2013	56.2	10.7	55	82.6	13.4	55	5.6	-26.40 [-30.93, -21.87]		
Q Yang 2015	45.6	61.5	50	75.6	24.5	50	2.4	-30.00 [-48.35, -11.65]	•	
RF Zhang 2014	32.6	21.5	57	31.1	20.4	55	4.8	1.50 [-6.26, 9.26]	-	- <b>-</b>
RQ Fan 2013	29.8	21.5	38	37.5	23.7	35	4.1	-7.70 [-18.11, 2.71]		+
SQ Pang 2013	20.3	5.1	50	45.2	32.1	50	4.4	-24.90 [-33.91, -15.89]		
XP Pan 2016	26.8	10.5	50	40.5	16.4	50	5.4	-13.70 [-19.10, -8.30]		
YH Gong 2010	30.6	12.3	28	47.6	10.6	24	5.2	-17.00 [-23.22, -10.78]		
YH Zeng 2013	54	33	30	83	37	30	2.5	-29.00 [-46.74, -11.26]	•	
YQ Zhao 2015	32.7	11.6	57	45	13.2	55	5.6	-12.30 [-16.91, -7.69]		
ZF Shangguan 2013	40.6	11.6	41	45.8	20.5	40	4.9	-5.20 [-12.48, 2.08]		+
ZG Wu 2017	31.9	20.8	45	33.6	20.3	47	4.6	-1.70 [-10.10, 6.70]		
ZH Hu 2016	27.82	10.14	43	39.87	11.4	43	5.6	-12.05 [-16.61, -7.49]		
ZJ Huang 2016	38.6	8.9	68	46.5	15.2	66	5.6	-7.90 [-12.13, -3.67]	_	
Total (95% CI)			1064			1056	100.0	-13.33 [-16.99, -9.68]	•	
Heterogeneity: tau <sup>2</sup> =				20 (P < 0.	.00001);	$I^2 = 86\%$		-50	-25	0 25 50
Test for overall effect	: Z = 7.15	(P < 0.0	0001)					-50	Favours (control)	Favours (experimental)

	Ex	perimer	ıtal		Control		Weight	Mean difference IV, random, 95% CI		Mean difference			
tudy or subgroup	Mean	SD	Total	Mean	SD	Total	(%)			IV, ran	dom, 95% CI		
C Xie 2016	31.54	14	50	29.77	15.28	50	5.2	1.77 [-3.97, 7.51]			<b></b>		
CR Shen 2010	52.6	27.3	46	54.5	35.6	50	3.4	-1.90 [-14.53, 10.73]			•		
Zhang 2017	35.5	10.7	35	51.7	13.4	35	5.3	-16.20 [-21.88, -10.52]					
L Long 2011	39.4	12.1	57	49.7	13.4	59	5.5	-10.30 [-14.94, -5.66]					
Q Chen 2016	29.5	14.8	45	41.2	16.9	45	5.0	-11.70 [-18.26, -5.14]					
IS Xie 2016	20.2	17.4	65	23.6	20.3	63	5.0	-3.40 [-9.96, 3.16]		_	+		
T Zhang 2015	34.8	24.9	100	39.5	19.5	100	5.1	-4.70 [-10.90, 1.50]			+		
Xiao 2010	63.3	19.5	54	67.3	17.4	54	4.9	-4.00 [-10.97, 2.97]			+		
L Wu 2013	46.8	12.8	55	83.8	23.4	55	4.9	-37.00 [-44.05, -29.95]		_			
Yang 2015	65.4	30.2	50	77.8	25.9	50	3.8	-12.40 [-23.43, -1.37]			-		
F Zhang 2014	34.6	25.2	57	34.8	23.7	55	4.3	-0.20 [-9.26, 8.86]		_			
Q Fan 2013	32.3	26.7	38	33.6	25.2	35	3.6	-1.30 [-13.21, 10.61]			•		
Q Pang 2013	30.3	6.2	50	39.4	11.3	50	5.7	-9.10 [-12.67, -5.53]					
P Pan 2016	25.5	9.5	50	37.6	10.5	50	5.7	-12.10 [-16.02, -8.18]					
H Gong 2010	34.6	10.2	28	43.6	11.6	24	5.2	-9.00 [-14.98, -3.02]			-		
H Zeng 2013	61	43	30	94	56	30	1.4	-33.00 [-58.27, -7.73]					
Q Zhao 2015	30.1	9.4	57	48.6	15.3	55	5.5	-18.50 [-23.22, -13.78]					
F Shangguan 2013	42.5	12.5	41	44.8	18.9	40	4.9	-2.30 [-9.30, 4.70]			•		
G Wu 2017	37.5	21.6	45	39.6	22.5	47	4.3	-2.10 [-11.11, 6.91]			•		
H Hu 2016	26.38	8.98	43	36.9	10.62	43	5.6	-10.52 [-14.68, -6.36]					
J Huang 2016	40.1	10.8	68	58.7	14.1	66	5.6	-18.60 [-22.86, -14.34]					
otal (95% CI)			1064			1056	100.0	-9.92 [-13.40, -6.44]		•			
leterogeneity: tau <sup>2</sup> =	51.67, ch	$i^2 = 133$	.97, df =	20 (P < 0	.00001);	$I^2 = 85\%$			50	1			
est for overall effect	: Z = 5.58	(P < 0.0	0001)						-50	-25	0 25		
										Favours (control)	Favours (expe	erimental)	

FIGURE 4: (a) The HBV-DNA negative conversion rate of TCM plus entecavir versus entecavir. (b) The ALT of TCM plus entecavir versus entecavir. (c) The AST of TCM plus entecavir versus entecavir.  $I^2$  and P are the criterion for the heterogeneity test,  $\blacklozenge$  pooled odds ratio,  $-\blacksquare$  odds ratio, and 95% CI.

publication bias in liver function indicators. We then compared and ranked all of the treatment strategies (Supplementary Tables 6 and 7, Figure 5) and obtained the average ranking of the various treatment strategies. We found that BRT (1), LWT (2.5), DZC (3.5), and FHC (4) were more effective as adjuvant drugs in improving liver function, but AHP (8) achieved the worst results. 3.1.4. Safety Assessment. A total of nine studies reported adverse events. These adverse reactions are mainly gastro-intestinal discomfort such as nausea, vomiting, mild diar-rhea, and loss of appetite; occasional allergies; and dizziness. However, none of the above symptoms were serious and disappeared after drug withdrawal. No related treatment was performed. Compared with the control group, the use of




FIGURE 5: (a) Ranking for efficacy of ALT; (b) ranking for efficacy of AST.

TCM did not have a significant impact on the incidence of adverse events. This shows that entecavir combined with TCM is safe in clinical use. In addition, details of the adverse events reported by the nine institutes are listed in the annex (Supplementary Table 8).

3.2. Discussion. Liver fibrosis caused by hepatitis B hepatitis is a reversible wound repair response characterized by the accumulation of extracellular matrix, which is the formation of scar tissue, which occurs after chronic or non-self-limiting liver disease, and it will eventually lead to cirrhosis. [45] In the world, the first-line drugs currently used are nucleoside (acid) analogues and interferon drugs, and their treatment cycles are generally long. In recent years, more and more research studies have found that TCM contains multiple active ingredients that can relieve or even reverse hepatitis B liver fibrosis. For example, Salvia miltiorrhiza and Cordyceps sinensis, they all have a variety of antifibrotic components, and in clinical use, there are many examples of using them to treat chronic hepatitis B liver fibrosis [46-48]. Rui's research further pointed out the pharmacological mechanisms of Salvia miltiorrhiza against liver fibrosis. The results of the study showed that Salvia miltiorrhiza water extract can inhibit the expression of GST-P and  $\alpha$ -SMA during the process of hepatic fibrosis, and the alanine transaminase, aspartate aminotransferase, y-glutamyltransferase, alkaline phosphatase, hyaluronic acid, direct bilirubin, and total bilirubin were significantly inhibited [49]. In addition, Peng et al. found that the main active components of Cordyceps sinensis against liver fibrosis are cordyceps polysaccharide, cordycepic acid, cordycepin, and ergosterol [50]. All these indicate that TCM is likely to play its unique role in the treatment of chronic hepatitis B liver fibrosis. Moreover, in long-term clinical practice, Chinese physicians have used and summarized many effective TCMs which are often combined with the current first-line drugs for the treatment of chronic hepatitis B liver fibrosis, and they were included in the Chinese Pharmacopoeia.

In this NMA, we found that 8 kinds of TCM as adjuvant medicines can improve liver fibrosis in patients with chronic hepatitis B liver fibrosis. The combination of FHC and entecavir is the best therapeutic strategy. It not only has a significant effect in improving the state of liver fibrosis in patients but also has a good effect in the improvement of liver function in patients. FZHY capsule is a commonly used TCM formula against liver fibrosis in clinic. It has been verified in research to exert antifibrosis effect through several mechanisms such as antilipid peroxidation and endothelial injury, inhibiting hepatic stellate cell activation, promoting matrix metalloproteinase activity, and degradation of pathological deposition of collagen. [51] In addition, there is an article using transcriptional profiling and miRNA-target network analysis to identify potential biomarkers for efficacy evaluation of FZHY formula-treated hepatitis B caused liver cirrhosis. [52] The use of AHP as an adjuvant drug in this study has shown a weaker effect and is lower than the single use of entecavir in the ranking, which is a very surprising result. In addition, the comprehensive evaluation results

showed that the addition of TCM did not appear to have a significant impact on the improvement of HBV-DNA negative conversion rates, but when the therapeutic strategies were compared individually, some of the therapeutic strategies showed a significant improvement in the negative conversion rates, which is worth in-depth explore the phenomenon. First, we considered whether the results of this study were affected by publication bias. For this purpose, we conducted relevant statistical tests and scissors funnel plot to determine whether there was publication bias. However, the results showed that there were no significant publication biases other than HBV-DNA negative conversion rates in the seven outcomes of this study. The inconsistency in our study of HBV-DNA negative conversion rates is likely due to publication bias in this outcome measure. Therefore, this has also weakened the strength of the evidence in this NMA, which in judging whether the combined use of Chinese and Western medicine can enhance the improvement of HBV-DNA negative conversion rates. Subsequently, in order to evaluate the stability of the results of this network metaanalysis, we performed a dual modeling analysis of the fixedeffects model and the random-effects model for all indicators in turn. As a result, it was found that only the LN and IV-C outcomes were slightly unstable in all indicators, and there was no contradictory research result, and the remaining outcomes all had good stability. This NMA includes many documents, there are differences in the size of the sample and there are many types of treatment strategies, so in the process of research, we also pay attention to the heterogeneity between the studies. We not only used literature analysis methods to explore the sources of heterogeneity but also used meta-regression analysis to conduct relevant research. As mentioned earlier, in evidence-based medicine research, there are often small sample sizes of studies, and these small sample studies often show relatively unstable results. Therefore, we first examine whether it caused the heterogeneity between studies by using the sample size as a variable. It was found that when we used the sample size as a variable for regression analysis, the Tau2 of HBV-DNA negative conversion rates was 0, so the difference in sample size was the source of the heterogeneity of the outcome. Therefore, this also reduces our ability to demonstrate whether TCM as an auxiliary drug can increase the HBV-DNA negative conversion rates in another aspect. However, it is worth noting that the heterogeneity of the remaining indicators does not originate from the sample size. Subsequently, we considered whether the heterogeneity between studies was caused by the large number of treatment decisions, and the results were as we suspected. Meta-regression analysis showed that this factor actually contributed 71.64% and 80.32% of the heterogeneity of HA and LN. In addition, the gender ratio of patients in this study is balanced, but the age difference among patients in some studies is likely to be one of the reasons for heterogeneity. However, because some studies did not provide detailed reports on the age of patients, we did not consider this factor as a variable for meta-regression analysis. In terms of drug safety, there was no serious adverse reaction after the use of TCM combined with entecavir, and the combined use of drugs did not increase the risk of adverse events. Therefore, the use of 8 kinds of TCM combined with entecavir is safe.

Although there are slight instability and bias in the results of this study and there are limitations in the quality of RCTs, these have reduced the strength of the NMA. However, overall, this NMA still provides clinicians with detailed comparisons of common therapeutic strategies and provides reference for clinical use. In addition, in the future, large-scale, high-quality RCTs should be conducted to further provide evidence that FHC has efficacy and safety as adjuvant drugs for the treatment of hepatitis B and liver fibrosis in clinical applications.

# 4. Conclusions

The NMA showed that compared with entecavir, combined TCM did not increase the risk of adverse reactions and could significantly improve the effect of chronic hepatitis B liver fibrosis. In addition, in a variety of therapeutic strategies, the combination of FHC and entecavir is the best therapeutic strategy. However, TCM as a complementary drug has not shown significant advantages in improving the HBV-DNA negative conversion rates. Finally, due to the low quality of the included studies, the strength of the research results is limited. Therefore, strict RCTs are still needed in the future to further validate the effectiveness and safety of FHC as an adjuvant drug for the treatment of chronic hepatitis B liver fibrosis.

#### **Data Availability**

All the data in this study have been uploaded.

# **Conflicts of Interest**

The authors declare that there are no conflicts of interest regarding the publication of this paper.

#### **Authors' Contributions**

Tao Wang and Wei Jin contributed equally to this work. Tao Wang, Yanling Zhao, and Haotian Li independently performed data extraction and quality assessment. Qianqian Huang and Huadan Cai formed a review team to independently verify the accuracy of data extraction, quality assessment, and all materials for this study. Tao Wang, Wei Jin, Yun Zhu, Honghong Liu, and Jiabo Wang are responsible for writing articles. Wenjun Zou, Yanling Zhao, Wei Jin, Ruilin Wang, and Xiaohe Xiao are responsible for the supervision and design of the entire study.

#### Acknowledgments

The current study was financially supported by the Project of Chinese Medicine Education Association (no. 2016SKT-Z003).

## **Supplementary Materials**

See Figures S1–S8 in the Supplementary Material for comprehensive image analysis, and see Tables S1–S8 for the raw data of the index in this study. (*Supplementary Materials*)

# References

- X. He, Y. Hong, X. Wang et al., "Identification and clinical significance of an elevated level of serum aminoacylase-1 autoantibody in patients with hepatitis B virus-related liver cirrhosis," *Molecular Medicine Reports*, vol. 14, no. 5, pp. 4255–4262, 2016.
- [2] X. Luo, Y. Huang, Y. Chen et al., "Association of hepatitis B virus covalently closed circular DNA and human APOBEC3B in hepatitis B virus-related hepatocellular carcinoma," *PLoS One*, vol. 11, no. 6, Article ID e0157708, 2016.
- [3] R. Lozano, M. Naghavi, K. Foreman et al., "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010," *Lancet (London, England)*, vol. 380, no. 9859, pp. 2095–2128, 2012.
- [4] V. Calvaruso and A. Craxì, "Fibrosis in chronic viral hepatitis," *Best Practice & Research Clinical Gastroenterology*, vol. 25, no. 2, pp. 219–230, 2011.
- [5] C. M. Lange, J. Bojunga, W. P. Hofmann et al., "Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function," *Hepatology*, vol. 50, no. 6, pp. 2001–2006, 2009.
- [6] Z. L. Yang and P. L. Yuan, "Clinical efficacy of combined use of traditional Chinese and western medicine in patients with Hepatitis B cirrhosis," *Journal of Guangxi Medical University*, vol. 2, pp. 330–332, 2016.
- [7] T. Wang, X. Zhou, H. Liu et al., "Fuzheng Huayu capsule as an adjuvant treatment for HBV-related cirrhosis: a systematic review and meta-analysis," *Phytotherapy Research*, vol. 32, no. 5, pp. 757–768, 2017.
- [8] X. L. Duan, G. Y. Li, S. M. Li et al., "Meta-analysis of influences of Fufang Biejia Ruangan Pian combined with entecavir on serum liver fibrosis markers of chronic hepatitis B," *Chinese Journal of Hospital Pharmacy*, vol. 35, no. 19, pp. 1762–1765, 2015.
- [9] Y. Zhou, H. Liu, J. Fang et al., "Meta-analysis of Liuwei wuling tablets combined with entecavir in the treatment of chronic hepatitis B," *China Pharmacy*, vol. 28, no. 36, 2017.
- [10] Z. Wen, Z. Wang, J. Zheng et al., "Meta-analysis on entecavir combined with anluohuaxian pills in the treatment of hepatitis B-related cirrhosis," *Guangming Journal of Chinese Medicine*, vol. 31, no. 12, 2016.
- [11] J. H. Zhang and X. F. Guo, "Clinical study of entecavir combined with Danshendi tablets for chronic hepatitis B liver fibrosis," *China Modern Medicine*, vol. 52, no. 20, pp. 49–51, 2014.
- [12] Y. J. Qiu, "Analysis of efficacy of entecavir combined with Danshendi tablets in treatment of chronic hepatitis B liver fibrosis," *Chinese Journal of Histochemistry & Cytochemistry*, vol. 32, no. 16, p. 1, 2017.
- [13] Y. Zou, "Clinical observation of entecavir combined with Danshendi tablets for chronic hepatitis B liver fibrosis," *Jilin Medical Journal*, vol. 36, no. 9, pp. 1748-1749, 2015.
- [14] Y. L. Fan, Y. Yuan, and Z. C. Feng, "Clinical study of entecavir combined with Danshendi tablets for chronic hepatitis B liver

fibrosis," China Modern Medicine, vol. 16, no. 13, pp. 5-6, 2009.

- [15] G. O. Chen, "Therapeutic effect of Liuwei wuling tablets combined with entecavir on chronic hepatitis B liver fibrosis," *The Journal of Medical Theory and Practice*, vol. 29, no. 5, pp. 629-630, 2016.
- [16] Q. Yang, "Therapeutic effect of Liuwei Wuling tablet combined with entecavir on chronic hepatitis B liver fibrosis," *Contemporary Medicine Forum*, vol. 13, no. 20, pp. 173-174, 2015.
- [17] Y. Q. Zhao, "Clinical efficacy of entecavir combined with Liuwei Wuling Tablets in treating chronic hepatitis B liver fibrosis," *Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases*, vol. 25, no. 6, pp. 364-365, 2015.
- [18] C. R. Shen, J. C. Guo, X. L. Yu et al., "Observation of the curative effect of entecavir combined with compound Biejia ruangan tablet on chronic hepatitis B liver fibrosis," *Journal of Zhejiang Chinese Medical University*, vol. 34, no. 3, pp. 370-371, 2010.
- [19] D. J. Chen, "Effect of entecavir combined with compound Biejia ruangan tablets on chronic hepatitis B liver fibrosis," *Chinese Healing Standard Management*, vol. 8, no. 28, pp. 111–113, 2017.
- [20] H. T. Zhang, X. Y. Zhang, Z. Y. Me et al., "Clinical observation on chronic hepatitis B liver fibrosis treated by compound Biejia ruangan tablets combined with entecavir," *Chinese Journal of Coal Industry Medicine*, vol. 18, no. 7, pp. 1120– 1122, 2015.
- [21] L. Xiao, Y. Y. Yang, L. Xu et al., "Clinical efficacy of entecavir combined with compound Biejia Ruangan tablets in treating chronic hepatitis B liver fibrosis," *China Medicine and Pharmacy*, vol. 3, no. 14, pp. 59-60, 2013.
- [22] R. F. Zhang, Y. J. Yao, Z. L. You et al., "Clinical observation on treatment of chronic hepatitis B liver fibrosis with fufang Biejia ruangan tablets combined with entecavir," *Journal of Third Military Medical University*, vol. 36, no. 18, pp. 1961– 1963, 2014.
- [23] X. L. Zhang, "Clinical effect of compound Biejia ruangan tablets combined with entecavir on chronic hepatitis B liver fibrosis," *China Metallurgical Industry Medical Journal*, vol. 33, no. 6, pp. 680-681, 2016.
- [24] Y. Y. Sun and Z. X. Zhu, "Clinical efficacy of entecavir combined with compound Biejia Ruangan tablets in treating chronic hepatitis B liver fibrosis," *Journal of Clinical Rational Drug Use*, vol. 10, no. 33, pp. 67-68, 2017.
- [25] Z. G. Wu, G. D. Zhou, Y. Y. Chen et al., "Clinical study on treatment of chronic hepatitis B liver fibrosis with compound Biejia ruangan tablets and entecavir," *Drug Evaluation Research*, vol. 40, no. 3, pp. 351–355, 2017.
- [26] Z. G. Zhang, "Effect of entecavir combined with compound Biejia ruangan tablets on chronic hepatitis B liver fibrosis," *Guide of China Medicine*, vol. 10, no. 36, pp. 456–458, 2012.
- [27] H. S. Xie, L. M. Cai, H. M. Yan et al., "Effect of entecavir combined with Fuzheng Huayu capsule on chronic hepatitis B liver fibrosis," *Zhejiang Medical Journal*, vol. 38, no. 8, pp. 555–557, 2016.
- [28] L. L. Wu, "Effect of entecavir and Fuzheng Huayu capsules on hepatic fibrosis in patients with chronic hepatitis B," *Modern Journal of Integrated Traditional Chinese and Western Medicine*, vol. 22, no. 35, pp. 3952-3953, 2013.
- [29] R. Q. Fan, C. Z. Su, G. J. Zhu et al., "Effect of entecavir combined with Fuzheng Huayu capsule on chronic hepatitis B liver fibrosis: a clinical observation of 73 cases," *Chinese*

Journal of Gastroenterology and Hepatology, vol. 22, no. 1, pp. 31-33, 2013.

- [30] S. Q. Pang, S. Wu, G. Q. Wang et al., "Entecavir combined with Fuzheng Huayu Capsule for treating 50 cases of chronic hepatitis B liver fibrosis," *China Pharmacy*, vol. 22, no. 8, pp. 120-121, 2013.
- [31] Y. H. Gong, J. J. Chen, J. H. Xue et al., "Combination of entecavir and Fuzheng Huayu capsule for 28 cases of chronic hepatitis B liver fibrosis," *Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases*, vol. 20, no. 2, pp. 119-120, 2010.
- [32] Y. Z. Song and T. T. Zhuang, "Therapeutic effect of Fuzheng Huayu capsule combined with entecavir on chronic hepatitis B liver fibrosis," *Fujian Medical Journal*, vol. 34, no. 6, pp. 89-90, 2012.
- [33] Z. F. Shuangguan, "Effect of entecavir and Fuzheng Huayu capsules on hepatic fibrosis in patients with chronic hepatitis B," *Chinese Journal of Rural Medicine and Pharmacy*, vol. 20, no. 1, pp. 39-40, 2013.
- [34] Y. C. Xie, G. X. Hu, Y. Z. Peng et al., "Therapeutic effect of Dahuang Zhechong capsule combined with entecavir on hepatic fibrosis in chronic hepatitis B," *Journal of Clinical Hepatology*, vol. 32, no. 8, pp. 1502–1507, 2016.
- [35] J. Shi, H. L. Tang, and C. Chen, "Dahuang Zhechong capsule combined with entecavir for chronic hepatitis B liver fibrosis in 20 cases," *Hunan Journal of Traditional Chinese Medicine*, vol. 29, no. 5, pp. 19-20, 2013.
- [36] X. P. Pan and Q. Dong, "Effect of entecavir combined with tanshinone capsule on liver fibrosis in patients with chronic hepatitis B," *Chinese Journal of Rural Medicine and Pharmacy*, vol. 23, no. 19, pp. 32-33, 2016.
- [37] Z. H. Hu and Y. H. Wu, "Entecavir and tanshinone capsules for the treatment of chronic hepatitis B liver fibrosis," *Zhejiang Journal of Integrated Traditional Chinese and Western Medicine*, vol. 26, no. 3, pp. 243–246, 2016.
- [38] X. Q. Chen, "Danshen injection combined with entecavir for chronic hepatitis B liver fibrosis," *Drugs & Clinic*, vol. 31, no. 6, pp. 878–881, 2016.
- [39] F. L. Long, H. Qiu, Y. Q. Chen et al., "Clinical observation on the treatment of chronic hepatitis B liver fibrosis with danshen injection combined with entecavir," *Guiding Journal of Traditional Chinese Medicine and Pharmacy*, vol. 17, no. 8, pp. 16-17, 2011.
- [40] F. Zhang and S. R. Li, "Clinical observation of entecavir combined with Anluo huaxian Pill in treating chronic hepatitis B liver fibrosis," *Military Medical Journal of South China*, vol. 31, no. 5, pp. 344-345, 2017.
- [41] H. D. Qi, Y. Yang, and S. J. Gong, "Therapeutic effect of Anluo huaxian Pill combined with entecavir on hepatic fibrosis in patients with chronic hepatitis B," *Modern Chinese Doctor*, vol. 11, pp. 88-89, 2008.
- [42] W. Guo, Y. Zhou, Y. S. Lu et al., "Treatment of chronic hepatitis B liver fibrosis with entecavir combined with anluohuaxian Pill," *Herald of Medicine*, vol. 29, no. 9, pp. 1157–1159, 2010.
- [43] Y. H. Zeng, "Clinical study on entecavir combined with anluohuaxian Pill in treating hepatitis B liver fibrosis," *Hubei Journal of Traditional Chinese Medicine*, vol. 35, no. 6, pp. 11-12, 2013.
- [44] Z. J. Huang and C. P. Zeng, "Treatment of liver fibrosis with HBeAg positive chronic hepatitis B in 134 patients with entecavir combined with Anluo Huaxian pills," *Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases*, vol. 26, no. 2, pp. 74-75, 2016.

- [45] Y. J. Cai, J. J. Dong, X. D. Wang et al., "A diagnostic algorithm for assessment of liver fibrosis by liver stiffness measurement in patients with chronic hepatitis B," *Journal of Viral Hepatitis*, vol. 24, no. 11, pp. 1005–1015, 2017.
- [46] L. L. Xiong, "Therapeutic effect of combined therapy of salvia miltiorrhiza and polyporus umbellatus polysaccharide in treating chronic hepatitis B," *Zhong Guo Zhong Xi Yi Jie He Za Zhi*, vol. 13, pp. 533–535, 1993.
- [47] F. Ye, Y. Liu, G. Qiu et al., "Clinical study on treatment of cirrhosis by different dosages of salvia injection," *Zhong Yao Cai*, vol. 28, pp. 850–854, 2005.
- [48] J. Peng, X. Li, Q. Feng, L. Chen, L. Xu, and Y. Hu, "Antifibrotic effect of Cordyceps sinensis polysaccharide: inhibiting HSC activation, TGF-β1/smad signalling, MMPs and TIMPs," *Experimental Biology and Medicine*, vol. 238, no. 6, p. 668, 2013.
- [49] W. Rui, L. Xie, X. Liu et al., "Compound Astragalus and Salvia miltiorrhiza extract suppresses hepatocellular carcinoma progression by inhibiting fibrosis and PAI-1 mRNA transcription," *Journal of Ethnopharmacology*, vol. 151, no. 1, pp. 198–209, 2014.
- [50] Y. Peng, Y. Y. Tao, Q. L. Wang et al., "Ergosterol is the active compound of cultured mycelium cordyceps sinensis on antiliver fibrosis," *Evidence-Based Complementary and Alternative Medicine*, vol. 2014, Article ID 537234, 12 pages, 2014.
- [51] T. Zhou, X. C. Yan, Q. Chen et al., "Effects of Chinese herbal medicine Fuzheng Huayu recipe and its components against hepatocyte apoptosis in mice with hepatic injury," *Journal of Chinese Integrative Medicine*, vol. 9, no. 1, pp. 57–63, 2011.
- [52] Q. Chen, F. Wu, M. Wang et al., "Transcriptional profiling and miRNA-target network analysis identify potential biomarkers for efficacy evaluation of fuzheng-huayu formula-treated hepatitis B caused liver cirrhosis," *International Journal of Molecular Sciences*, vol. 17, no. 6, p. 883, 2016.